Pfizer and AstraZeneca's jabs are 'just as effective' in the immunosuppressed, ...

Pfizer and AstraZeneca's jabs are 'just as effective' in the immunosuppressed, ...
Pfizer and AstraZeneca's jabs are 'just as effective' in the immunosuppressed, ...
Pfizer and AstraZeneca's jabs are 'just as effective' in the immunosuppressed and patients with underlying health conditions, real-world data shows There were lingering fears the jabs would work less well in those at risk groups But first real-world data shows two doses reduce symptomatic illness risk by 74% This is just as effective as in rest of the population, Public Health England said

View
comments

Pfizer and AstraZenca's vaccines are just as effective in people with underlying health conditions and the immunosuppressed, real-world data shows.

There were lingering fears the jabs would work less well in those groups because they have a harder time mounting a strong immune response.

Insurance Loans Mortgage Attorney Credit Lawyer

But the first data from Britain's vaccine rollout shows both vaccines reduce the risk of symptomatic illness by about 74 per cent after two doses.

Public Health England said the jabs were 'as effective... in the majority of people with underlying health conditions compared to the rest of the population’. 

Even after one dose, vaccine effectiveness against symptomatic disease was around 60 per cent and did not fall substantially with age. 

An estimate for the jabs' impact on severe disease, hospitalisation and death has not yet been established but it is expected to be even higher.

However, the analysis looked specifically at older versions of the virus and so the efficacy numbers could be slightly lower against the now-dominant Indian variant.

Pfizer and AstraZenca's vaccines are just as effective in people with underlying health conditions and the immunosuppressed, real-world data shows

Pfizer and AstraZenca's vaccines are just as effective in people with underlying health conditions and the immunosuppressed, real-world data shows

Broken down, PHE said that after two doses for those aged 16 to 64, Pfizer/BioNTech offered 93 per cent protection, while AstraZeneca/Oxford offered 78 per cent.

For those aged 65 and over, two doses of Pfizer gave 87 per cent protection while AstraZeneca offered 76 per cent.

For people who are immunosuppressed, vaccine effectiveness after a second dose was 74 per cent, with similar protection to those who are not in an at-risk group.

Insurance Loans Mortgage Attorney Credit Lawyer

This rises from 4 per cent after a first dose, showing the importance of a second dose.

Some health conditions are linked to an increased risk of hospital admission and death from Covid-19, including diabetes, severe asthma, chronic heart, kidney or liver disease, neurological disease, and illnesses or therapies that weaken the immune system, such as blood cancer, HIV or chemotherapy.

PHE said that protection for these people against

read more from dailymail.....

NEXT US fencer, 29, accused of sexual assault, confronts teammates after they wear ...